Press "Enter" to skip to content

Bayer says it is looking into established drugs strategy

"We’re looking strategically, obviously, what to do with our more established products business in the long haul," divisional head Stefan Oelrich, who joined Bayer in November last year, told analysts in a conference call.

Original source:

Also Read:   Lupin gets 6 observations from USFDA for its Pithampur Unit-2